A very recent clinical study (LuTectomy Trial) investigated the use of [177Lu]Lu-PSMA-617 as neo-adjuvant therapy prior to radical prostatectomy in patients with localized, high-risk prostate cancer [63]. The gene discussed is FOLH1; the disease is prostate cancer.